InflammoPharmacology

, Volume 5, Issue 3, pp 237–246 | Cite as

Anti-inflammatory activity of a lipid fraction (lyprinol) from the NZ green-lipped mussel

  • M. W. Whitehouse
  • T. A. Macrides
  • N. Kalafatis
  • W. H. Betts
  • D. R. Haynes
  • J. Broadbent
Article

Abstract

A lipid-rich extract, preparared by supercritical fluid extraction of fresh stabilized mussel powder (Lyprinol), showed significant anti-inflammatory (AI) activity given therapeutically and prophylactically po to Wistar and Dark Agouti rats developing either (a) adjuvant-induced polyarthritis or (b) collagen(II)-induced autoallergic arthritis, with ED50≤15 mg/kg; c.f. naproxen≥25 mg/kg or various therapeutic oils (flaxseed, evening primrose, fish)≥1800 mg/kg given orally. Lyprinol showed little or no activity in acute irritation assays (carrageenan, kaolin, histamine) indicating it is not mimicking rapid-acting NSAIDs.

Incorporating Lyprinol into arthritigenic adjuvants composed of heat-killed Mycobacterium. tuberculosis suspended in olive oil or squalane, effectively prevented arthritis development at a dose of 5 mg/rat. By contrast, ‘dummy adjuvants’ prepared with Mycobacterium tuberculosis and flaxseed, evening primrose or fish oils were still arthritigenic in Dark Agouti rats (doses of oil=90 mg/rat).

Lyprinol subfractions inhibited leukotriene-B4 biosynthesis by stimulated human polymorphonuclear leukocytes in vitro, and prostaglandin-E2 production by activated human macrophages in vitro. Much of this AI activity was associated with polyunsaturated fatty acids and natural antoxidants (carotenoids, etc.).

In contrast to NSAIDs, Lyprinol is non-gastrotoxic in disease-stressed rats at 300 mg/kg po and does not seem to affect platelet aggregation (human, rat). These data show Lyprinol to be a reproducible, relatively stable, source of bioactive lipids with much greater potency than plant/marine oils currently used as nutritional supplements to ameliorate signs of inflammation.

Keywords

NZ green-lipped mussel Lyprinol Lipid fraction Inflammation NSAIDs 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Croft JE. Relief from arthritis: a safe and effective treatment from the ocean. Wellingborough (UK): Thorsons Publishers; 1979:128.Google Scholar
  2. 2.
    Zwar D. The magic mussel—arthritis another way? 2nd edn. Cairns, Australia: Ideas Unlimited. 1994:108.Google Scholar
  3. 3.
    Gibson RD, Gibson SLM, Conway V, Chappell D. Perna canaliculus in the treatment of arthritis. Practitioner. 1980;224:955–60.PubMedGoogle Scholar
  4. 4.
    Gibson RD, Gibson SLM. Green-lipped mussel extract in arthritis. Lancet. 1981;i:149.Google Scholar
  5. 5.
    Gibson RD, Gibson SLM. Seatone in arthritis. Br Med J., 1981;283:1472.Google Scholar
  6. 6.
    Audeval B, Bouchacourt P. Etude controle en double aveugle contra placebo de l'extrait de moule Perna canaliculus dans la gonarthrose. Gaz Medicale. 1986;38:111–16.Google Scholar
  7. 7.
    Highton TC, McArthur AW. Pilot study on the effect of NZ green lipped mussel on rheumatoid arthritis. NZ Med J. 1975;80:261–3.Google Scholar
  8. 8.
    Huskisson EC, Scott J, Bryans R. Seatone is ineffective in rheumatoid arthritis. Br Med J. 1981;282:1358–9.CrossRefGoogle Scholar
  9. 9.
    Caughey DE, Grigor RR, Caughey EB, Young P, Gow PJ, Stewart AW. Perna canaliculus in the treatment of rheumatoid arthritis. Eur J Rheumatol Inflamm. 1983;6:197–200.PubMedGoogle Scholar
  10. 10.
    Larkin JG, Capell HA, Sturrock RD. Seatone in rheumatoid arthritis: a six-month placebo-controlled study. Ann Rheum Dis. 1985;44:199–201.PubMedCrossRefGoogle Scholar
  11. 11.
    Couch RA, Ormrod DJ, Miller TE, Watkins WR. Anti-inflammatory activity in fractionated extracts of the green-lipped mussel. NZ Med J. 1982;95:803–6.Google Scholar
  12. 12.
    Miller TE, Dodd J, Ormrod DJ, Geddes R. Anti-inflammatory activity of glycogen extracted from Perna canaliculus (NZ green-lipped mussel). Agents Actions. 1993;38:C139–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Rainsford KD, Whitehouse MW. Gastroprotective and anti-inflammatory properties of green-lipped mussel (Perna canaliculus) preparation. Arzneim-forsch. 1980;30:2128–32.Google Scholar
  14. 14.
    Cullen JC, Flint MJ, Leider J. The effects of dried mussel extract on an induced polyarthritis in rats. NZ Med J. 1975;81:260–1.Google Scholar
  15. 15.
    Kosuge T, Tsugi K, Ishida H, Yamaguchi T. Isolation of an anti-histaminic substance from green-lipped mussel (Perna canaliculus). Chem Pharm Bull. 1986;34:4825–8.PubMedGoogle Scholar
  16. 16.
    Miller T, Wu H. In vivo evidence for prostaglandin activity in New Zealand green-lipped mussel extract. NZ Med J. 1984;97:355–7.Google Scholar
  17. 17.
    Broadbent JM, Kosuge Y. Stabilised mussel extract. NZ Patent 211928 (29 April 1985); Australian patent PG 4775/84 (1 May 1984).Google Scholar
  18. 18.
    Macrides T, Kalafatis N. Lipid extract having anti-inflammatory activity. Int. Patent application PCT/AU 96/00564.Google Scholar
  19. 19.
    Macrides T, Kalafatis N. Anti-inflammatory preparation. Int. Patent application PCT/AU 95/00485.Google Scholar
  20. 20.
    Cremer M. Type II collagen-induced arthritis in rats. In: Greenwald RA, Diamond HS, eds. Handbook of Animal Models for the Rheumatic Diseases, Vol. 1. Boca Raton: CRC Press; 1988:17–27.Google Scholar
  21. 21.
    Betts WH, Hurst NP, Murphy GA, Cleland LG. Auranofin stimulates LTA hydrolase and inhibits 5-lipoxygenase/LTA synthase activity of isolated human neutrophils. Biochem Pharmacol. 1990;39:1233–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Haynes DR, Garrett IR, Whitehouse MW, Vernon-Roberts B. Do gold drugs inhibit interleukin-1? Evidence from an in vitro lymphocyte assay. J Rheumatol. 1988;15:775–8.PubMedGoogle Scholar
  23. 23.
    Kelly RW, Deam S, Cameron MJ, Seamark FR. Measurement by radioimmunoassay of prostaglandins as their methyl oximes. Prostaglandins Leukotrienes Med. 1987;24:1–14.CrossRefGoogle Scholar
  24. 24.
    Prickett JD, Trentham DE, Robinson DR. Dietary fish oil augments the induction of arthritis in rats immunised with type II collagen. J Immunol. 1984;132:725–9.PubMedGoogle Scholar
  25. 25.
    Haynes DR, Gadd SJ, Whitehouse MW, Mayrhofer G, Vernon-Roberts B. Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporine-A and lobenzarit. Inflamm Res. 1996;45:159–65.PubMedCrossRefGoogle Scholar
  26. 26.
    Macrides TA, Treschow AP, Kalafatis N, Wright PFA. The anti-inflammatory effects of Omega 3 tetraenoic fatty acids isolated from a lipid extract (Lyprinol) from the New Zealand, green-lipped mussel. Abstr. 88th American Oil Chemists Society Annual Meeting, Seattle, May, 1997.Google Scholar
  27. 27.
    Calder PC. Immunomodulatory and anti-inflammatory effects of n-3 polyunsaturated fatty acids. Proc Nutr Soc. 1996;55:737–74.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • M. W. Whitehouse
    • 1
  • T. A. Macrides
    • 2
  • N. Kalafatis
    • 2
  • W. H. Betts
    • 3
  • D. R. Haynes
    • 4
  • J. Broadbent
    • 5
  1. 1.Department of Medicine, University of QueenslandPrincess Alexandra HospitalBrisbaneAustralia
  2. 2.Department of Medical Laboratory ScienceRoyal Melbourne Institute of TechnologyAustralia
  3. 3.Rheumatology UnitThe Queen Elizabeth HospitalWoodvilleAustralia
  4. 4.Department of PathologyUniversity of AdelaideAustralia
  5. 5.McFarlane LaboratoriesSurrey HillsAustralia

Personalised recommendations